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5-aminosalicylic acid (5-ASA) is an antiinflammatory drug widely used in the treatment of 
inflammatory bowel diseases. It is known to inhibit the production of cytokines and 
inflammatory mediators, but the mechanism underlying the intestinal effects of 5-ASA 
remains unknown. Based on the common activities of peroxisome proliferator–activated 
receptor-
 

 
 (PPAR-
 

 
) ligands and 5-ASA, we hypothesized that this nuclear receptor 
mediates 5-ASA therapeutic action. To test this possibility, colitis was induced in heterozygous 
PPAR-
 

 

 
/
 

 
 mice and their wild-type littermates, which were then treated with 5-ASA. 5-ASA 
treatment had a beneficial effect on colitis only in wild-type and not in heterozygous mice. 
In epithelial cells, 5-ASA increased PPAR-
 

 
 expression, promoted its translocation from the 
cytoplasm to the nucleus, and induced a modification of its conformation permitting the 
recruitment of coactivators and the activation of a peroxisome-proliferator response element–
driven gene. Validation of these results was obtained with organ cultures of human colonic 
biopsies. These data identify PPAR-
 

 
 as a target of 5-ASA underlying antiinflammatory 
effects in the colon.
 
5-aminosalicylic acid (5-ASA) is among the
oldest antiinflammatory agents in use today for
the treatment of Crohn’s disease and ulcerative
colitis, two major human forms of chronic in-
flammatory bowel diseases (IBDs). In 1942,
5-ASA was initially combined with an antibiotic
sulfapyridine in a molecule named sulphasala-
zine (1). Thirty-five years later, Azad Khan et
al. demonstrated that 5-ASA was the therapeu-
tically active moiety of this drug with proven
antiinflammatory effects in IBDs (2). After oral
or rectal administration, 5-ASA acts locally in
the colon and is absorbed by colonic epithelial
cells (3–5). The effectiveness of the drug is re-
lated to its mucosal concentration (6), and sys-
temic dosages remain low after oral sulphasal-
azine and rectal 5-ASA administration (7). The
putative antiinflammatory actions of 5-ASA
include modulation of inflammatory cytokine
production (8), decreased transcriptional activity
of NF-
 

 
B by modulating RelA/p65 phos-
phorylation (9), and inhibition of the biosyn-
thesis of prostaglandins and leukotrienes (10).
However, despite these numerous experimental
studies, the basic mechanism of action of 5-ASA
remains unknown.
Peroxisome proliferator–activated receptors
(PPARs) are members of the nuclear receptor
superfamily. They are activated by fatty acids
and are involved in the transduction of meta-
bolic and nutritional signals into transcriptional
responses (11). Among these transcription factors,
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PPAR-
 

 
 plays an important role in the maintenance of mu-
cosal integrity in the intestine (12). Expressed at high levels in
the colonic epithelium, PPAR-
 

 
 and its high-affinity syn-
thetic ligands such as thiazolidinediones are involved in the
regulation of colon inflammation (12–15). Based on the
common activities of 5-ASA and PPAR-
 

 
 ligands in colonic
epithelial cells, we hypothesized that PPAR-
 

 
 may be the
molecular target of 5-ASA. In the present study, we report
that chemically induced colitis in mice heterozygous at the
PPAR-
 

 
 locus (PPAR-
 

 

 
/
 

 
) was refractory to 5-ASA ther-
apy. Using the HT-29 colon epithelial cell line, we found
that 5-ASA induced PPAR-
 

 
 mRNA and protein expres-
sion. Furthermore, the ability of 5-ASA to bind and activate
PPAR-
 

 
 in different experimental settings including receptor
binding, transcriptional activation, and conformational changes
indicated that 5-ASA exerts its effects in the colon through
direct PPAR-
 

 
 activation.
 
RESULTS
Colon inflammation in PPAR-
 

 

 
/
 

 
 mice is refractory to 
5-ASA therapy
 
Intrarectal administration of 2,4,6-trinitrobenzene sulfonic
acid (TNBS) to male 129/Sv mice provoked a severe colitis,
which represents a well-validated model that has many mac-
roscopic and histologic similarities to human IBDs (Fig. 1 A)
(16–18). In nontreated animals killed 5 d after colitis induc-
tion, weight loss and severe macroscopic and histologic le-
sions that would have resulted in death were observed in
50% of mice (Fig. 1). These lesions, characterized by large
areas of ulceration, necrosis, and a transparietal neutrophilic
infiltration, were scored by macroscopic and histologic eval-
uation as 5.2 
 

 
 0.8 and 2.6 
 

 
 1.2, respectively, according to
the multiparametric Wallace and Ameho criteria (19, 20).
The most clinically effective dosage of a controlled-release
5-ASA preparation given orally was investigated in these
conventional 129/Sv mice by a detailed dose–response study
of dosages ranging from 50 mg/kg/d to 1,000 mg/kg/d (Fig.
1, B–D). Evolution of weight curves was similar in control
mice without colitis and mice receiving TNBS and treated
with 5-ASA at 100, 500, and 1,000 mg/kg, but not with
5-ASA at 50 mg/kg (Fig. 1 B). These data were used to
eliminate the 5-ASA dosage of 50 mg/kg. Because 5-ASA at
100 mg/kg was the concentration of 5-ASA closest to that used
to treat IBDs in humans (21), and because the therapeutic ef-
fects of 5-ASA on body-weight changes (Fig. 1 B), mortality
rate (Fig. 1 C), and macroscopic Wallace scores (Fig. 1 D)
were statistically similar for the dosages of 100, 500, and
1,000 mg/kg, we selected 100 mg/kg as the optimal con-
centration of 5-ASA for the following study in PPAR-
 

 

 
/
 

 
mice. At this concentration of 5-ASA, improvements in
body-weight changes, mortality rate, and Wallace scores
were similar those seen in the rosiglitazone-positive mice
(Fig. 1, B–E). A significant decrease in colonic methyl per-
oxidase (MPO) and TNF-
 

 
 mRNA concentrations used as
biological markers of inflammation paralleled this improve-
ment (Fig. 1 F). To determine whether the antiinflammatory
effects of 5-ASA in the colon were mediated by PPAR-
 

 
,
colitis was induced in 129/Sv PPAR-
 

 

 
/
 

 
 mice by intrarec-
tal TNBS administration. Compared with their wild-type
littermates, these heterozygous knockout mice had a mean
70 
 

 
 8% decrease of PPAR-
 

 
 mRNA levels in the colon.
As established previously (17), PPAR-
 

 

 
/
 

 
 mice exhibited
more pronounced macroscopic/histologic lesions and higher
concentrations of biological markers of inflammation than
wild-type animals (Fig. 1, E and F). In contrast with control
mice, 5-ASA treatment did not affect the severity of TNBS
colitis in PPAR-
 

 

 
/
 

 
 mice, as assessed by macroscopic or
histologic scores, colonic MPO, or TNF-
 

 
 concentrations
(Fig. 1, E and F), indicating PPAR-
 

 
 may have a major role
in mediating the antiinflammatory effect of 5-ASA.
 
5-ASA induces differentiation of 3T3-L1 cells
 
Most ligands of PPAR-
 

 
 are potent and effective at stimulat-
ing adipogenesis in preadipocyte cell lines expressing PPAR-
 

Figure 1. Colon inflammation in PPAR- heterozygous mice is 
refractory to 5-ASA therapy. (A) Colitis was induced by intrarectal ad-
ministration of TNBS in wild-type mice (black) and PPAR/ mice (gray). 
Animals were killed 5 d later to evaluate the intensity of colitis. (B–D) A 
detailed dose–response study was performed with oral 5-ASA given daily 
and compared with untreated animals with colitis (control) or receiving an 
optimal dosage (20 mg/kg) of rosiglitazone (rosi). 5-ASA effects were ana-
lyzed according to the evolution of (B) body weight, (C) mortality, and (D) 
macroscopic Wallace scores. (E and F) To evaluate whether the antiinflam-
matory role of 5-ASA in the colon was mediated by PPAR-, we compared 
the antiinflammatory effects of the most efficient dosage of 5-ASA in 
wild-type mice (black) and in PPAR/ mice (gray). In contrast with wild-
type mice, 5-ASA was ineffective in PPAR/ mice and did not modify (E) 
macroscopic and histologic lesions evaluated by the Wallace and Ameho 
scores, respectively, or (F) the colonic molecular markers of inflammation 
such as myeloperoxidase (MPO) and the production of TNF-. The number 
of mice and statistical significance are indicated. Results are expressed as 
the mean  SEM. *, P  0.05 compared with untreated mice with colitis; 
, P  0.01 compared with untreated mice with colitis.
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such as 3T3-L1 cells (22). To evaluate the role of 5-ASA as
a PPAR-
 

 
 activator, we compared the effects of different
concentrations of 5-ASA and of the thiazolidinedione rosi-
glitazone on confluent 3T3-L1 preadipocytes at day 8 after
confluence. Optimal dosage of rosiglitazone (10
 

 
5
 
 M) en-
hanced intracytosolic accumulation of lipid as monitored by
Oil Red O staining in 94 
 

 
 3% of cells (Fig. 2). Treatment
with 5-ASA also induced a marked differentiation of preadi-
pocytes in a dose-dependant manner leading to lipid accu-
mulation in 98 
 

 
 1% of cells (Fig. 2). Lactate dehydrogenase
activity remained low and was not modified in the presence
of rosiglitazone or 5-ASA (unpublished data), ensuring that
5-ASA did not exert a direct cytotoxic effect on 3T3-L1
cells. These data establish that 5-ASA has an adipogenic ca-
pacity similar to that of rosiglitazone.
 
Induction and activation of PPAR-
 

 
 expression in 
5-ASA–treated epithelial cells
 
Experiments in cultured preadipocyte suggest that activation
of PPAR-
 

 
 by rosiglitazone modestly increases the expres-
sion of this receptor in a positive-feedback loop (23, 24). We
then compared the capacity of 5-ASA and of rosiglitazone to
induce PPAR-
 

 
 expression at the mRNA and protein levels
in the HT-29 cell line. A threefold induction of PPAR-
 

 
mRNA expression quantified by real-time PCR technique
was found in colonic epithelial cells treated for 12 h with
5-ASA, 30 mM (Fig. 3 A). Western blot extended and
confirmed these results, showing a threefold induction of
PPAR-
 

 
 protein levels in cells treated by 5-ASA, 30 mM,
and a twofold induction of PPAR-
 

 
 protein levels in cells
treated by rosiglitazone, 10
 

 
5 
 
M (Fig. 3 B).
We also investigated PPAR-
 

 
 transcriptional activity by
transient transfections (13). Analysis of PPAR-
 

 
 activity in
transfected HT-29 cells showed that 5-ASA at 30 mM in-
creased the reporter-gene activity by threefold, thereby dis-
playing an activity similar to that of rosiglitazone (Fig. 3 C).
 
Binding of 5-ASA to PPAR-
 

 
 induces activation
 
Activation of PPAR-
 

 
 results in a cascade of reactions in-
cluding translocation or redistribution of PPAR-
 

 
 in the cell
nucleus (25, 26), conformational changes within PPAR-
 

 
(27, 28), recruitment of coactivators, and binding to specific
DNA sequence elements termed peroxisome-proliferator re-
sponse elements (PPRE) (29–31). The effects of 5-ASA–
bound PPAR-
 

 
 were examined at these different steps.
Intracellular localization of PPAR-
 

 
 in epithelial cells has
not been characterized previously. In other cell types, dis-
tinct PPAR-
 

 
 localizations have been observed (25, 26, 32).
Using fluorescence microscopy to visualize the cellular dis-
tribution of a GFP-tagged PPAR-
 

 
, a predominantly cyto-
plasmic distribution of the fluorescent label was found in
unstimulated HT-29 cells (Fig. 4 A). This cytoplasmic
localization of PPAR-
 

 
 in epithelial cells has been noted
previously ex vivo by immunohistochemistry in the colonic
epithelial cells of patients (13). Exposure of epithelial cells to
different concentrations of 5-ASA (1 mM, 5 mM, or 30
Figure 2. 5-ASA induces differentiation of 3T3-L1 cells. The adipo-
genic effect of different concentrations of 5-ASA (from 104 M to 102 M) 
was evaluated in 3T3-L1 preadipocytes and compared with rosiglitazone 
(rosi, 105 M). After 4 d of culture, only 17  4% of cells incubated with 
medium alone (control) showed enhanced intracytosolic accumulation of 
lipid droplets monitored by Oil Red O (ORO) staining. Treatment with the 
different concentrations of 5-ASA and rosiglitazone induced a marked dif-
ferentiation of 3T3-L1 cells. Results are expressed as the mean  SEM 
number of stained cells counted in four different experiments.
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mM) for 24 h resulted in a similar redistribution of GFP-
tagged PPAR- to the nucleus (Fig. 4, A and B). The trans-
location of GFP-tagged PPAR- from the cytoplasm to the
nucleus was also observed with rosiglitazone.
Next, to evaluate the conformational changes induced by
the binding of 5-ASA to PPAR-, we performed a protease
protection assay of [35S]-PPAR- bound to either 5-ASA or
rosiglitazone. Rosiglitazone binding did not lead to a radical
change in the proteolytic pattern as compared with 5-ASA
(Fig. 5). As previously described, rosiglitazone-positive con-
trol induced a conformational change in PPAR- as assessed
by the generation of two protease-resistant bands following
partial chymotrypsin digestion of [35S]-PPAR- (Fig. 5 and
references 27, 28). 5-ASA also generated protease-resistant
fragments different from those observed with rosiglitazone,
indicating that 5-ASA induces structural transitions in PPAR-
distinct from those induced by rosiglitazone.
Recruitment of transcriptional coactivators plays a cen-
tral role in mediating transcriptional activity of liganded
PPAR-. Among these coactivators, vitamin D3 receptor–
interacting protein (DRIP)-205 is an important coactivator
interacting directly with PPAR- (31, 33). To study the ef-
fect of 5-ASA binding to PPAR-, we examined whether
5-ASA-bound PPAR- can bind to DRIP-205. Glu-
tathione S-transferase (GST) pull-down assays with [35S]-
PPAR- incubated with either 5-ASA (1 and 5 mM) or
rosiglitazone and a GST-DRIP-205 fusion protein were
performed. The results clearly showed that, like the control
rosiglitazone, 5-ASA was able to bind and to activate
PPAR- resulting in an increased interaction between [35S]-
PPAR- and GST-DRIP (Fig. 6). The maximal efficacy of
5-ASA (5 mM) was 150% of that observed with rosiglita-
zone (105 M), suggesting that in these conditions the forma-
tion of PPAR-–DRIP complexes was more pronounced
with 5-ASA than with rosiglitazone.
Taken together, these observations point to the produc-
tive binding of 5-ASA to PPAR-, inducing a coordinated
cascade of reactions leading to the translocation of PPAR-
in the cell nucleus, a modification of its conformation per-
mitting the recruitment of coactivators and activation of a
PPRE-driven reporter gene.
5-ASA binding assay for PPAR- and docking studies
The direct binding of 5-ASA to PPAR- was explored by
competitive ligand-binding assay using radioactive rosiglita-
zone. Because rosiglitazone is located in the ligand-binding
pocket of the PPAR- ligand-binding domain (LBD) in the
crystal structure of the complex (34), loss of rosiglitazone
binding would demonstrate that 5-ASA displaces it. As pre-
viously described, in a competitive experiment the com-
mercially available PPAR- ligand GW1929 displaced
[3H]rosiglitazone used as positive control from the PPAR-
LBD with a Ki value of 60 nM (Fig. 7 A and reference 35).
5-ASA also displaced [3H]rosiglitazone from the PPAR-
LBD with a Ki value of 28.7 mM (Fig. 7 B). The concentra-
tion of 5-ASA that caused 50% inhibition (IC50) of rosiglita-
zone binding was 15.2 mM. This IC50 of 5-ASA corresponds
to the efficient 5-ASA concentrations (1–50 mM) found in
vivo in treated patients (36, 37).
Docking simulations were performed to predict the
binding mode of 5-ASA into the active site of PPAR- for-
merly occupied by rosiglitazone (38). One of the most sta-
ble docking models showed a binding mode of 5-ASA sim-
ilar to the crystal orientation of the thiazolidinedione head
group of rosiglitazone (Fig. 8, A and B). 5-ASA fitted
Figure 3. Induction and activation of PPAR- expression in 5-ASA–
treated epithelial cells. (A) PPAR- mRNA expression was quantified by 
real-time PCR in HT-29 STD cells incubated for 3, 6, 12, 18, 24, and 48 h 
with 5-ASA (30 mM) or rosiglitazone (105 M). The main induction of 
PPAR- mRNA expression was observed at 12 h in cells incubated with 
5-ASA. Results were expressed as the mean  SEM of six different experi-
ments. (B) The level of PPAR- protein expression was evaluated by Western 
blot assay in untreated HT-29 cells (control) and after 24 h of 5-ASA (30 mM) 
or rosiglitazone (rosi, 105 M) treatment. OD values of PPAR- were given 
for each condition in proportion to the quantity of the internal control 
-actin in the same sample. (C) Activation of PPAR- by 5-ASA. HT-29 
STD cells transfected with the response element for PPAR- (2XCYP) and 
treated by 5-ASA (30 mM) or rosiglitazone (105 M) showed a similar, 
approximately threefold induction of PPAR- reporter gene activity indi-
cating the ability of 5-ASA to induce PPAR- activation. Results are ex-
pressed as fold activation (mean  SEM) compared with untreated cells.
JEM VOL. 201, April 18, 2005 1209
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tightly with the PPAR- LBD interacting via hydrogen
bonding with His-323, His-449, Tyr-473, and Ser-289,
which are considered key determinants for molecular rec-
ognition and PPAR- activation (Fig. 8, C and D, and ref-
erences 34, 39). The phenolic hydroxyl group of 5-ASA did
not interact with the receptor, but its orientation favored an
intramolecular hydrogen bond with the carboxyl group as
shown in its crystal structure (40). Superimpositions of our
5-ASA model to other known PPAR- head group ligands
such as the PPAR-–bound crystallographic conformations
of tesaglitazar (AZ242) (39) and farglitazar (GI262570) (38)
showed a similar PPAR- binding mode of 5-ASA and gli-
tazars (Fig. 8 E).
5-ASA induces PPAR- expression and activation in human 
colonic mucosa
To validate the previous results obtained in vitro and in vivo
in mice, we evaluated the effects of 5-ASA in organ cultures
of right colonic biopsies taken in healthy mucosa of 12 un-
treated patients (6 non-IBD patients, 3 patients with Crohn’s
Figure 4. Intracellular localization of PPAR- in epithelial cells. 
(A) HT-29 STD cells transfected with GFP-tagged PPAR- were incubated 
in the presence of medium alone (unstimulated cells), 5-ASA (30 mM), or 
rosiglitazone (rosi, 105 M) for 24 h. Nuclear staining in blue was per-
formed with Hoescht 33342 solution. The intracellular distribution of the 
fluorescent tags was examined under a fluorescence microscope. (B) HT-29 
STD cells transfected with GFP-tagged PPAR- incubated in the presence 
of 5-ASA (30 mM) for 24 h. Green color represents PPAR- (left); blue 
color represents the nucleus (middle); merged green and blue pictures 
illustrate the translocation of PPAR- into the cell nucleus (right).
Figure 5. Protease protection assay of PPAR- in presence of 5-ASA 
or rosiglitazone. Difference in protease sensitivity of 5-ASA–bound and 
rosiglitazone-bound PPAR- compared with nonliganded PPAR- (con-
trol). Autoradiogram of an SDS-PAGE gel showing [35S]methionine-labeled 
full-length human PPAR-2 digested with chymotrypsin. Asterisks and 
arrow denote chymotrypsin-resistant and chymotrypsin-sensitive-protein 
fragments, respectively.
Figure 6. GST pull-down assays with PPAR- incubated with 5-ASA 
or rosiglitazone. The GST-DRIP fusion protein bound to glutathione-
sepharose beads was incubated with medium alone (control), 5-ASA 
(1 and 5 mM), or rosiglitazone (105 M) in the presence of [35S]methionine-
labeled PPAR-. Autoradiograms of SDS-PAGE gel show higher amounts 
of the coactivator DRIP bound to PPAR- in the presence of 5-ASA and 
rosiglitazone than in the control. The amount of PPAR- bound to coacti-
vator in the presence of the indicated ligands is expressed as fold induc-
tion relative to that measured in absence of ligand (control, defined as 1). 
Each sample was processed in duplicate.
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disease, and 3 patients with ulcerative colitis). After 24 h in a
5% CO2 chamber, treatment of 5-ASA at 1, 30, and 50 mM
increased expression of PPAR- mRNA and its target gene
NGAL (Fig. 9 and reference 41). Release of lactic dehydrog-
enase from specimens in culture remained low and stable
over the 24-h period. No change in lactic dehydrogenase re-
lease was induced by the presence of 5-ASA in the incuba-
tion medium.
DISCUSSION
Although 5-ASA therapy has been widely used in patients
with IBD, the general mechanism underlying its antiinflam-
matory effects in the colon remain incompletely character-
ized. In the present study, we demonstrate that PPAR- is
the key receptor for 5-ASA that mediates its main effects in
the colon. This determination is based on multiple func-
tional, pharmacological, and chemical lines of evidence and
was validated in vivo in a murine model of IBD and with
human clinical samples.
After oral or rectal administration into the colon, some
5-ASA is absorbed by colonic epithelial cells, but most remains
within the lumen and is passed in the stool (3–5). In IBD pa-
tients receiving standard 5-ASA maintenance treatment, the
median mucosal concentrations of 5-ASA are 16 ng/mg,
ranging from 3 to 50 ng/mg of wet colonic tissues (2). The
therapeutic effect of 5-ASA depends more on the direct con-
tact of the molecule with the epithelium of the colon than on
the tissue concentration of 5-ASA in the colon, indicating
that a high perimucosal concentration of 5-ASA is a prereq-
Figure 7. 5-ASA binding assay for PPAR-. A competitive binding 
assay was performed with 40 nM [3H]-rosiglitazone in the presence or 
absence of (A) PPAR- agonist GW1929 (0–800 nM, Sigma-Aldrich) used 
as positive control or (B) increasing concentrations of nonradioactive 
5-ASA (0–100 mM). 5-ASA competed with rosiglitazone for binding to 
PPAR-. The specific binding obtained with [3H]rosiglitazone alone was 
100% of control. Results are expressed as the mean  SEM in four differ-
ent experiments.
Figure 8. Docking simulation of the PPAR- binding mode of 5-ASA. 
Comparison of the interaction of (A) rosiglitazone and (B) 5-ASA colored by 
atom type in the ligand-binding domain (LBD) represented by a green sur-
face in the X-ray crystal structure of PPAR- displayed as a blue ribbon. 
(C) 5-ASA displayed in space-filling representation colored by atom type 
fitted tightly within the PPAR- LBD represented as a white surface. 
(D) Key hydrogen binding interactions (dotted line) between 5-ASA and 
PPAR-. (E) Similar binding mode of 5-ASA model and crystallographic 
conformation of tesaglitazar, farglitazar, and rosiglitazone.
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uisite for its action. It has been previously reported in patients
conventionally treated with 5-ASA that stool concentrations
of 5-ASA are in the median order of 30 mM, ranging from
10 to 100 mM; these concentrations correspond to luminal
concentrations of 5-ASA 100 times greater than the concen-
trations in the colonic mucosa (2, 7, 34, 42, 43). In vitro,
these millimolar concentrations of 5-ASA (1–50 mM) are
able to inhibit signal transduction (44), cell proliferation (45),
and expression of the inducible nitric oxide synthase (46).
Taken together, these data indicate that the 5-ASA concen-
trations between 1 and 50 mM used in the present study are
clinically and biologically relevant and may be even below
the 5-ASA concentrations found intraluminally in IBD pa-
tients receiving 5-ASA maintenance treatment.
We have previously shown that PPAR- is expressed at
the highest levels in adipose tissue and the colonic epithe-
lium (12, 13, 47, 48). Best characterized as a regulator of cel-
lular metabolism and adipocyte differentiation, PPAR- is
also capable of inhibiting the inflammatory response in sev-
eral experimental models of colitis induced either by the ad-
ministration of dextran sodium sulfate (14, 15) or 2, 4,
6-TNBS (17) and by ischemia-reperfusion (49). Based on the
common antiinflammatory functions of 5-ASA and PPAR-
in epithelial cells and the high expression of PPAR- by the
colon epithelial cells that 5-ASA targets, we hypothesized
that 5-ASA may be a new functional ligand of PPAR-. Us-
ing clinically relevant 5-ASA concentrations (36, 37), we
showed by transfection studies using GFP-tagged PPAR-,
a PPAR-–sensitive reporter gene, protease protection as-
says, and GST pull-down assays that 5-ASA is able to bind
PPAR-, to induce its translocation from the cytosol of epi-
thelial cells to the nucleus, to promote a PPAR- conforma-
tional change, and to induce recruitment of a coactivator.
Evidence supporting 5-ASA as a direct functional agonist
of PPAR- was obtained with a ligand-binding assay and by
using 3T3-L1 cells. PPAR- is a master regulator of adipo-
cyte differentiation, and this effect has been well demon-
strated with the 3T3-L1 cells, which required PPAR- acti-
vation for their differentiation (22). We showed that, like
the PPAR- ligand rosiglitazone, 5-ASA is an inducer of ad-
ipogenesis resulting in the conversion of 3T3-L1 preadipo-
cytes into adipocytes. The relevance of these in vitro data
was further demonstrated in an experimental model of colitis
in mice treated with a controlled-release 5-ASA preparation
developed to deliver the drug in the colon and to minimize
its systemic absorption in the proximal intestine (3–5). In-
deed, PPAR-/ mice with colitis induced by intrarectal
administration of TNBS were completely refractory to
5-ASA preventive treatment, whereas the same dosage of
5-ASA given to wild-type mice with the same genetic back-
ground significantly attenuated the inflammatory response in
the colon. Besides this therapeutic effect of 5-ASA given
preventively, we and others have also shown that, after in-
duction of colitis by dextran sodium sulfate or TNBS, ad-
ministration of PPAR- ligands is always effective in reduc-
ing lesion intensity and mortality compared with untreated
mice, despite destruction of the epithelial cell layer (14, 17).
The mechanisms involved in the therapeutic effects of
PPAR- ligands in established intestinal lesions remain par-
tially unknown. It is possible that expression of PPAR- in
the colon by immune cells such as macrophages and lym-
phocytes residing in the lamina propria may play a role (50,
51). Because the spontaneous fluorescent properties of
5-ASA enable its localization in macrophages and lympho-
cytes of the lamina propria after oral or rectal administration
(52), we can hypothesize that during 5-ASA administration,
PPAR- expressed by macrophages and T cells may be acti-
vated in vivo and may induce antiinflammatory effects in the
gut, as previously described (15, 53).
Regulation of PPAR- expression in epithelial cells re-
mains completely unknown. There is evidence that activa-
tion of PPAR- by thiazolidinedione in preadipocytes can
increase modestly the expression of this receptor in a posi-
tive-feedback loop (23, 24). In HT-29 colonic epithelial
cells treated with 5-ASA, we observed a threefold induction
of PPAR- expression at the mRNA and protein levels.
These results obtained by quantitative real-time PCR paral-
leled those found in organ cultures of human colonic biop-
sies and by Western blot analysis at the protein level in epi-
thelial cell line. These data suggest that 5-ASA is able to bind
and activate PPAR- and also may enhance its expression.
This point is particularly important in patients with ulcer-
ative colitis characterized by a chronic inflammation of the
colon in which PPAR- expression is decreased in colonic
epithelial cells (13).
Taken together, these data make a compelling case that
5-ASA is a novel PPAR- agonist and show that PPAR- is
the major functional receptor mediating the common
5-ASA activities in IBD. Several X-ray studies of PPAR-
crystal structures revealed the binding mode of synthetic
Figure 9. 5-ASA induces PPAR- expression and activation in 
organ cultures of human colonic biopsies. Levels of PPAR- mRNA 
(red) and its target gene NGAL (blue) quantified by real-time PCR in human 
colon biopsies after 24 h of culture with medium alone and three concen-
trations of 5-ASA (1, 30, and 50 mM). Results are expressed as the fold 
induction (mean  SEM) compared with control (medium). The number of 
patients and statistical significance are indicated. *, P  0.05 compared 
with controls; , P  0.05 compared with 5-ASA (1 mM); ˆ, P  0.05 com-
pared with 5-ASA (30 mM).
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PPAR- agonists such as glitazones and glitazars in the LBD
of the receptor (38, 39). In our study, we identified 5-ASA
as a new synthetic PPAR- ligand interacting with the
LBD. Because 5-ASA was originally developed without any
knowledge of its molecular target, there is hope that the re-
search described here will lead to the rational optimization
or development of better PPAR- ligands. Improvements in
efficacy may reside in a new compound with higher affinity
or an association of agents with additive or synergic effects
on the PPAR-/retinoid x receptor (RXR) heterodimer.
Studies are also in progress to evaluate if quantification of
PPAR- expression in the intestinal mucosa of patients may
be a marker for monitoring therapeutic effectiveness of
5-ASA. By analogy with glitazones or glitazars, other studies
should also be done to assess whether 5-ASA could have
therapeutic effects in patients with metabolic disorders.
MATERIALS AND METHODS
5-ASA, GW1929 (N-aryl tyrosine activator), and 2, 4, 6-TNBS were pur-
chased at Sigma-Aldrich. Rosiglitazone was acquired at Spi Bio. [3H]rosi-
glitazone was synthesized at Isobio.
Induction of TNBS colitis and study design. Animal experiments
were performed in accredited establishments at the Institut de Génétique et
de Biologie Moléculaire et Cellulaire in Strasbourg (B59-108 and B 67–
218-5) and at the Institut Pasteur from Lille (86/609/CEE) according to
governmental guidelines. Animals were housed five per cage and had free
access to standard mouse chow and tap water. For colitis induction, mice
were anesthetized for 90–120 min and received an intrarectal administration
of TNBS (40 	l, 150 mg/kg) dissolved in a 1:1 mixture of 0.9% NaCl with
100% ethanol (13, 18). Control mice received a 1:1 mixture of 0.9% NaCl
with 100% ethanol or a saline solution using the same technique. Animals
were killed 5 d after TNBS administration. The antiinflammatory effects of
5-ASA were evaluated by administration of different dosages of a con-
trolled-release 5-ASA preparation (50 mg/kg/d–1,000 mg/kg/d) and com-
pared with the PPAR- ligand rosiglitazone used at the optimal dosage of
20 mg/kg in 129/Sv wild-type and PPAR-/ mice (Fig. 1 and reference
17). 5-ASA was administered orally once daily, starting 2 d before colitis in-
duction. Body-weight changes and macroscopic and histological indications
of colitis were evaluated blindly by two investigators. The colon of each
mouse was examined under a dissecting microscope (at a magnification of 5)
to evaluate the macroscopic lesions according to the Wallace criteria. The
Wallace score rates macroscopic lesions on a scale from 0 to 10 based on
features reflecting inflammation, such as hyperemia, thickening of the
bowel, and extent of ulceration (19). A colon specimen located precisely 2
cm above the anal canal was used for histological evaluation according to
the Ameho criteria (20). This grading on a scale from 0 to 6 takes into ac-
count the degree of inflammation infiltrate, the presence of erosion, ulcer-
ation, or necrosis, and the depth and surface extension of lesions. The other
parts of the colon were frozen and used to quantify PPAR-, MPO, and
TNF- mRNA levels (16, 17).
Cell lines. 3T3-L1 preadipocytes (ATCC CL-173) were grown to conflu-
ence in DME (Invitrogen) with 10% FCS and antibiotics. The medium was
supplemented with 1 	M dexamethasone, 0.2 mM isobutyl methyl xan-
thine, 10 	g/ml insulin, and 10% FCS for 2 d (27). The effects of 5-ASA
(104 M–102 M) on the differentiation of 3T3-L1 preadipocytes into adi-
pocytes were compared with the effects of rosiglitazone (105 M) on con-
fluent cells over 8 d. Medium, 5-ASA, and rosiglitazone were changed every
2 d. Cell viability was assessed by testing lactate dehydrogenase activity in
the culture medium taken during the course of the differentiation process or
on mature 3T3-L1 cells, treated or not with rosiglitazone and 5-ASA. Adi-
pogenesis was scored by staining lipids with Oil Red O. Counts of at least
500 cells/sample were systematically performed blindly in four different ex-
periments. Results were expressed as the mean  SEM number of stained
cells per experiment.
The colon carcinoma cell line HT-29 STD (American Type Culture
Collection; HTB-38) was routinely grown in DME supplemented with
10% heat-FCS and antibiotics. Cells were grown in monolayers, incubated
in 5% CO2 at 37
C and 95% relative humidity.
Real-time mRNA quantification. Total RNA was isolated from cells
and colonic tissues using Rneasy kit (Macherey Nagel) according to the
manufacturer’s instructions. RNA quantification was performed using spec-
trophotometry. After treatment at 37
C for 30 min with 20–50 units of
RNase-free DNase I (Roche Diagnostics Corp.), oligo-dT primers (Roche
Diagnostics Corp.) were used to synthesize single-stranded cDNA. mRNAs
were quantified using SYBR green Master Mix (Applera Corp.) with
specific mouse oligonucleotides: TNF-, forward, 5-TGGGAGTAGA-
CAAGGTACAACCC-3, reverse, 5-CATCTTCTCAAAATTCGAGT-
GACAA-3; and human oligonucleotides: PPAR-, forward, 5-CCT-
GATAGGCCCCACTGTGT-3, reverse, 5-CAGGTGGGAGTGGAA-
CAAT-3 and NGAL, forward, 5-TTCAGGGAGGCCCAAAGA-3, re-
verse, 5-CCTCTACGGGAGAACCAAGGA-3 in a GeneAmp Abiprism
7000 (Applera Corp.). In each assay, calibrated and no-template controls
were included. Each sample was run in triplicate. SYBR green dye intensity
was analyzed using the Abiprism 7000 SDS software (Applera Corp.). All
results were normalized to the unaffected housekeeping gene -actin:
mouse -actin, forward, 5-GGGTCAGAAGGATTCCTATG-3, reverse,
5-GGTCTCAAACATGATCTGGG-3 and human -actin, forward, 5-
TCACCCACACTGTGCCCATCTACG-3, reverse, 5-CAGCGGAA-
CCGCTCATTGCCAATG-3 (16).
Evaluation of PPAR, -actin, and MPO by Western blot analysis.
Total proteins were obtained by cell or colon homogenization in an extrac-
tion buffer consisting of PBS with 2% triton, 100 mM PMSF, and a classical
protease-inhibitor cocktail. Total proteins were then separated by PAGE
and electroblotted. Polyvinylidendifluoride membranes were incubated
overnight with rabbit polyclonal primary antibody directed against PPAR-
(dilution 1/500, Tebu Bio) or MPO (dilution 1/500; DakoCytomation)
(13, 17). -actin was detected using a rabbit monoclonal primary antibody
diluted at 1/10,000 (Sigma-Aldrich). Immunodetection with a swine sec-
ondary peroxidase-conjugated antibody (1/1,000; DakoCytomation) and
chemiluminescence were performed according to manufacturer’s protocol
(ECL, Amersham Biosciences). MPO results were expressed as units of OD
per quantity of total protein. OD values of PPAR- were given for each
condition in proportion to the quantity of the internal control -actin in
the sample.
GFP-tagged PPAR-. 1 	g of GFP-tagged PPAR- vector was trans-
fected in HT-29 STD cells using the Effectene transfection reagent
(QIAGEN). After 24 h incubation, cells were treated with 5-ASA (1 mM, 5
mM, or 30 mM) or with rosiglitazone (105 M) for 1 d. After two PBS
washes, cells were fixed by 4% paraformaldehyde. Nuclei were stained with
Hoescht 33342 solution, 0.125 mg/ml (Sigma-Aldrich). Slides were
mounted and visualized under a fluorescence microscope (Leica).
Protease digestion assay. [35S]Methionine-labeled full-length human
PPAR-2 was generated using transcription/translation system (Promega)
according to the manufacturer’s instructions. 1 	l of labeled PPAR-2, di-
luted in binding buffer (10 mM Hepes, pH 7.4; 100 mM KCl; 2 mM
dithiothreitol; 10% glycerol), was incubated with 5-ASA (5 mM) or rosigli-
tazone (105 M) for 120 min at 4
C and submitted to chymotrypsin diges-
tion as previously described (54). This high concentration of rosiglitazone
was used to ensure complete receptor saturation. Different concentrations
of chymotrypsin (0, 1, 3, 6, 9, and 12 U; Sigma-Aldrich) were added to the
mix for 30 min at 25
C. The reaction was terminated by the addition of 15
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	l of 3 denaturing gel loading buffer and by boiling for 1 min. Proteolysis
products were separated by electrophoresis through a 12% SDS-PAGE gel.
After electrophoresis, gels were dried, and radioactivity was detected with a
Storm 860 phosphoimager (Molecular Dynamics).
GST pull-down experiments. The protocol used has been published
elsewhere (55). In brief, 5–10 pmol (5 	l) of [35S]-labeled human PPAR-
was incubated with the indicated concentration of ligand in a 200-	l final
volume. The binding buffer consisted of 20 mM Tris-HCl, pH 7.5, 150
mM NaCl, 10% glycerol, 0.1% Triton X-100. After 1 h incubation at 20
C,
40 	l of GST-DRIP slurry was added to the mix and agitated slowly on a
rotating wheel for 90 min at 20
C. Unbound material was removed by
three successive washes of sepharose beads by 10 volumes of 1 phosphate-
buffered saline 0.1% Triton X-100. Resin-bound receptors were then re-
solved by SDS-PAGE on a 10% gel and detected by autoradiograph with a
Storm 860 phosphoimager (Molecular Dynamics). The amount of PPAR-
bound to coactivator in the presence of the indicated ligands was expressed
as fold-induction relative to that measured in the absence of ligand (defined
as 1). Each sample was processed in duplicate.
Transient transfection with PPAR- and stimulation of cells. HT-
29 STD cells were transiently transfected using the Effectene transfection
reagent (QIAGEN) according to instructions from the manufacturer. To
test PPAR- activation, we performed transfection with 500 ng of a mini-
mal promoter construct containing two copies of PPRE obtained from the
cytochrome p450 4A (2XCYP) (13). The renilla luciferase plasmid (0.1 	g/
well) was also transfected as an internal control for monitoring transfection
efficiency and for normalizing the firefly luciferase activity. Transfected cells
were incubated for 48 h at 37
C. Stimulations were performed for 6 h with
5-ASA 30 mM or with the PPAR- synthetic ligand rosiglitazone 105 M
used as positive control. Total cell extracts were prepared using the Passive
Lysis Buffer (Promega). Luciferase activity was assayed in 20 	l of the ex-
tract using Promega’s Dual Luciferase assay system according to the manu-
facturer’s protocol. Transfections were assayed in triplicate in at least three
separate experiments. The luciferase activity was expressed as fold of the ac-
tivity obtained in cells treated with 5-ASA dividing by luciferase activity
from nonstimulated cells.
Competition binding assay for PPAR-. Ligand-binding assays were
processed as described previously (56). In brief, purified PPAR-–LBD (In-
vitrogen) was incubated at 4
C for 2–3 h in 100 	l of buffer A (50 mM
Tris, pH 8.0, 100 mM KCl, 100 	g/ml OVA, 0.3% ([3-cholamidopropyl-
dimethylammonio]-1-propanesulfonate), and 10 mM dithiothreitol) with
40 nM [3H]rosiglitazone in the presence of increasing concentrations of un-
labeled 5-ASA (0–100 mM) or the known PPAR- agonist GW1929
(0–800 nM, Sigma-Aldrich) used as positive control. 40 nM is the concen-
tration of [3H]rosiglitazone usually required for competition experiments,
yielding a reversible 80% saturation of the receptor (27). Bound radioactive
ligand was separated from free radioactive ligand by incubating samples for
10 min at 4
C with 50 	l of a charcoal-dextran suspension (3% charcoal,
0.3% dextran in buffer A) and was quantified by liquid scintillation count-
ing. Each assay was performed in triplicate. Ki values were calculated ac-
cording to the equation of Cheng and Prusoff corresponding to Ki  IC50/
(1 [L]/Kd) where L is the concentration of [3H]rosiglitazone (40 nM), and
the Kd for rosiglitzone is 45 nM (57).
Molecular modeling. Molecular modeling studies were performed using
SYBYL software version 6.9 (Tripos Associates Inc.) running on Silicon
Graphics workstations. A three-dimensional model of the zwitterion form
of 5-ASA was built from a standard fragments library, and its geometry was
subsequently optimized using the Tripos force field (58) including the elec-
trostatic term calculated from Gasteiger and Hückel atomic charges. Pow-
ell’s method, available in Maximin 2 (SYBYL 6.9; Tripos Associates) proce-
dure, was used for energy minimization until the gradient value was smaller
than 0.001 kcal/mol Å. The structure of the human PPAR- ligand-bind-
ing domain was obtained from its complexed X-ray crystal structure with
the rosiglitazone available in the Research Collaboratory for Structural Bio-
informatics Protein Data Bank (1FM6) (38). Flexible docking of 5-ASA
into the receptor active site was performed using GOLD software (Cam-
bridge Crystallographic Data Centre; reference 59). The most stable dock-
ing models were selected according to the best-scored conformation pre-
dicted by the GoldScore (59) and X-Score scoring functions (60). The
complexes were energy-minimized using the Powell method available in
Maximin2 procedure with the Tripos force field and a dielectric constant of
4.0 until the gradient value reached 0.01 kcal/mol Å. The anneal function
was used to define a 10-Å hot region and a 15-Å region of interest around
the ligand.
Patients and organ culture. Six endoscopically normal right colonic bi-
opsies were taken with an endoscopic forceps on surgical specimens from 12
untreated patients operated on for Crohn’s disease (n  3), ulcerative colitis
(n  3), or colon cancer (n  6). The study was approved by the local eth-
ics committee. Biopsies were immediately placed in HBSS–calcium or
magnesium free supplemented with 100 IU/ml penicillin and 100 mg/ml
streptomycin. After washing, biopsies were incubated in a humidified atmo-
sphere for 1 d at 37
C in six-well tissue-culture plates containing 2 ml of
RPMI 1640 supplemented with 1, 30, or 50 mM 5-ASA (61). Supernatants
were removed, filtered, and stored at 80
C for determination of lactate
dehydrogenase release, and biopsies were processed to quantify PPAR-
and NGAL mRNA.
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